Form 4: Revolution Medicines COO Executes $7.5M Stock Sale

Revolution Medicines' Chief Operating Officer, Margaret Horn, reported exercising stock options and selling 75,000 shares of common stock for over $7.5 million under a pre-arranged 10b5-1 trading plan.

Summary

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc., reported transactions on January 7, 2026.
• Exercised stock options to acquire a total of 75,000 shares of common stock.
• Acquired 51,406 shares at an exercise price of $42.45 per share.
• Acquired 23,594 shares at an exercise price of $29.80 per share.
• Sold a total of 75,000 shares of common stock.
• Sold 53,096 shares at a weighted average price of $100.0164 per share.
• Sold 20,204 shares at a weighted average price of $101.7928 per share.
• Sold 1,700 shares at a price of $102.90 per share.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2025.
• Following these transactions, Margaret Horn beneficially owns 141,053 shares of common stock, which includes 61,226 restricted stock units.
• Remaining derivative securities include 1,094 stock options with an exercise price of $42.45 and 119,906 stock options with an exercise price of $29.80.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a significant number of shares were sold by a key executive, the transactions were pre-planned under a 10b5-1 plan, which is a common practice for executive liquidity and tax management. The sales occurred at prices significantly above the exercise price, indicating personal financial gain rather than a negative outlook on the company.

Positives

• The Chief Operating Officer exercised stock options, indicating the options were in-the-money and valuable.
• The sale of shares occurred at prices significantly higher than the exercise prices, demonstrating substantial personal gain for the insider.
• The transactions were conducted under a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations and suggests pre-planned liquidity events rather than reactive selling.

Negatives

• A significant number of shares (75,000) were sold by a key executive, which could be interpreted by some investors as a reduction in direct equity exposure, despite being part of a 10b5-1 plan.
• The total proceeds from the sale exceeded $7.5 million, representing a substantial reduction in the executive's direct common stock holdings.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide specific industry context. However, insider trading activity, even under a 10b5-1 plan, is closely watched by the market as it can sometimes reflect an executive's personal financial planning or perception of the company's future prospects within its competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the significant sale by a COO with mixed feelings; some may see it as a routine liquidity event, while others might interpret it as a signal, despite the 10b5-1 plan.

Key Dates

Recommendation

The filing details routine insider transactions by the Chief Operating Officer, Margaret Horn, involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. While the sale of 75,000 shares for over $7.5 million is substantial, it's a common practice for executives to manage their equity compensation and personal finances. The transactions do not provide new fundamental information about Revolution Medicines' operational performance or strategic direction. Therefore, based solely on this Form 4, a 'hold' recommendation is appropriate, as it neither presents a strong buy signal nor a significant red flag that would warrant a 'sell' recommendation.

Keywords

Revolution Medicines, RVMD, Form 4, insider trading, stock options, share sale, COO, Margaret Horn, 10b5-1 plan, executive compensation, equity